Kynurenine 3-monooxygenase polymorphisms: Relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 1, 2012, Pages 53-57

  Holtze, Maria ^a   Saetre, Peter ^a   Engberg, Göran ^a   Schwieler, Lilly ^a   Werge, Thomas ^b   Andreassen, Ole A ^c   Hall, Håkan ^a   Terenius, Lars ^a   Agartz, Ingrid ^a,d   Jönsson, Erik G ^a   Schalling, Martin ^a   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Mental Health Services CPH   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; PERPHENAZINE; RACLOPRIDE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE COMPLEX; FEMALE; GENE SYNTHESIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUMBAR PUNCTURE; MALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84255168900     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.100175     Document Type: Article

References (46)

1. Luby ED, Cohen BD, Rosenbaum G, et al. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959;81:363-9.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
3. Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamineinduced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999;156:1646-9.
4. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008;31:234-42.
5. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009;23:91-101.
6. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-30.
7. Erhardt S, Blennow K, Nordin C, et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-8.
8. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005;80:315-22.
9. Ganong AH, Cotman CW. Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 1986;236:293-9.
10. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988;154:85-7.
11. Kessler M, Baudry M, Lynch G. Quinoxaline derivatives are highaffinity antagonists of the NMDA receptor-associated glycine sites. Brain Res 1989;489:377-82.
12. Parsons CG, Danysz W, Quack G, et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997;283:1264-75.
13. Hilmas C, Pereira EF, Alkondon M, et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001;21:7463-73.
14. Erhardt S, Oberg H, Mathe JM, et al. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 2001;20:353-62.
15. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmaco - logically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002;175:45-53.
16. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 2006;113:557-71.
17. Linderholm KR, Andersson A, Olsson S, et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 2007;53: 918-24.
18. Erhardt S, Schwieler L, Emanuelsson C, et al. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004;56:255-60.
19. Geyer MA, Swerdlow NR, Mansbach RS, et al. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 1990;25:485-98.
20. Geyer MA, Krebs-Thomson K, Braff DL, et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54.
21. French ED, Mura A, Wang T. MK-801, phencyclidine (PCP), and PCPlike drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 1993;13:108-16.
22. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999;375: 87-100.
23. Hamshere ML, Bennett P, Williams N, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to Drosoph Inf ServC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry 2005;62:1081-8.
24. Ekelund J, Hennah W, Hiekkalinna T, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 2004;9:1037-41.
25. Karayiorgou M, Gogos JA. Schizophrenia genetics: uncovering positional candidate genes. Eur J Hum Genet 2006;14:512-9.
26. Kirov G, O'Donovan MC, Owen MJ. Finding schizophrenia genes. J Clin Invest 2005;115:1440-8.
27. Aoyama N, Takahashi N, Saito S, et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav 2006;5:364-8.
28. Holtze M, Saetre P, Erhardt S, et al. Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study. Schizophr Res 2011;127:270-2.
29. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008;66:87-98.
30. Nilsson LK, Nordin C, Jönsson EG, et al. Cerebrospinal fluid kynurenic acid in male and female healthy controls - correlation with monoamine metabolites and influence of confounding factors. J Psychiatr Res 2007;41:144-51.
31. Kepplinger B, Baran H, Kainz A, et al. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2- microglobulin changes. Neurosignals 2005;14:126-35.
32. Okamoto H, Yamamoto S, Nozaki M, et al. On the submitochondrial localization of l-kynurenine-3-hydroxylase. Biochem Biophys Res Commun 1967;26:309-14.
33. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105-32.
34. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2010 Aug. 10. [Epub ahead of print].
35. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010;36:211-8.
36. Speciale C, Wu HQ, Cini M, et al. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 1996;315:263-7.
37. Atlas A, Gisslen M, Nordin C, et al. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun 2007;21: 86-91.
38. Guillemin G J, Smythe G, Takikawa O, et al. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005;49:15-23.
39. Holtze M, Asp L, Schwieler L, et al. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res 2008;86:3674-83.
40. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3- dioxygenase. Int J Biochem Cell Biol 2007;39:2167-72.
41. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
42. Söderlund J, Schröder J, Nordin C, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009;14:1069-71.
43. Miller CL, Llenos IC, Dulay JR, et al. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004;15:618-29.
44. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2010 Oct. 29. [Epub ahead of print].
45. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, et al. Chronic neuro - leptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006;113:1355-65.
46. Miller CL, Llenos IC, Dulay JR, et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006;1073-1074:25-37.